EP2651385A2 - Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle - Google Patents

Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle

Info

Publication number
EP2651385A2
EP2651385A2 EP11787643.3A EP11787643A EP2651385A2 EP 2651385 A2 EP2651385 A2 EP 2651385A2 EP 11787643 A EP11787643 A EP 11787643A EP 2651385 A2 EP2651385 A2 EP 2651385A2
Authority
EP
European Patent Office
Prior art keywords
acid
polyquaternium
hair treatment
alcohol
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11787643.3A
Other languages
German (de)
English (en)
Inventor
Marcus Krueger
Marlene Battermann
Thomas Hippe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP2651385A2 publication Critical patent/EP2651385A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/002Preparations for repairing the hair, e.g. hair cure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/004Preparations used to protect coloured hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners

Definitions

  • the present invention relates to hair treatment compositions containing dicocoyl pentaerythrityl distearyl citrate.
  • Dicocoyl pentaerythrityl distearyl citrate is used in the hair treatment composition of the present invention as part of an active ingredient complex.
  • the compositions of the invention are further characterized in that no silicone is included.
  • a care complex should be provided which can ideally also be used in conjunction with oxidizing agents and surface-active agents.
  • silicones as in the case of cyclic silicones, could possibly influence living organisms more strongly than assumed. Also influences of colorations, bleaching or permanent waves after a previous hair wash with Silikonhaitigen hair treatment agents are reported.
  • Another object is to formulate these hair treatment agents free of any silicones, but with the usual properties of the silicones.
  • the oxidative treatment keratin braver fibers, especially human hair, with the application of an effective fiber protection from environmental influences, such as UV protection are connected.
  • the commercial product Cutina® Shine is a complex fatty acid ester made from coconut fatty acid, pentaerythritol stearyl alcohol and citric acid. Dicocoyl pentaerythrityl distearyl citrate. This raw material is recommended by the manufacturer, the company Cognis, for use in hair care products. Furthermore, it is pointed out in the data sheets that with Cutina® Shine a significantly increased deposition and thus an increase in the degree of effect of the silicones can be achieved.
  • This active ingredient complex improves the finish, improves the gloss, improves the moisture balance and protects the destructuring of keratin-containing fibers, in particular human hair, by UV radiation and, more particularly, to protect against oxidative damage, in particular to maintain hair growth, to prevent it hair loss and prevention of greasing of the keratinic fibers, and to increase the washing resistance of dyed keratinic fibers.
  • a first object of the present invention is therefore a hair treatment composition containing - based on its weight - a) 0.001 to 5 wt .-% dicocoyl pentaerythrityl distearyl citrates and
  • radicals R are each independently a saturated or unsaturated, linear or branched hydrocarbon radical having a chain length of 8 to 30 carbon atoms and A is a physiologically acceptable anion, and / or
  • quaternized cellulose derivatives in particular Polyquaternium 10 and / or Polyquaternium 67, and / or cationic alkyl polyglycosides and / or
  • the cosmetic agents are used to treat keratinous fibers, in particular human hair.
  • Preferred agents according to the invention are therefore, for example, shampoos, hair dyes, conditioners or hair tonics.
  • the grip defines the tactility of a fiber collective, whereby the expert sensoryly senses and evaluates the parameters fullness and suppleness of the collective.
  • Shaping is understood to mean the ability to give a shape change to a group of previously treated keratin-containing fibers, in particular human hair. Hair cosmetics also speak of hair styling.
  • an oxidative cosmetic agent containing at least one oxidizing agent on hair in a cosmetic carrier is defined according to the invention.
  • the hair treatment composition comprising the active substance complex according to the invention is preferably used immediately before, during or after the oxidative or surfactant hair treatment.
  • an application directly followed by the oxidative or surfactant hair treatment wherein the active ingredient complex containing hair treatment agent previously rinsed from the hair or preferably left on the hair and the hair is preferred still wet.
  • an application which follows either directly on the oxidative or surfactant hair treatment is understood as meaning after the oxidative or surfactant hair treatment, wherein the hair treatment agent containing the active substance complex according to the invention after rinsing the oxidatively or surfactant acting on the preferably still wet, towel-dried hair is applied, or applied to dry or wet hair only after several hours or days.
  • the hair treatment composition according to the invention can be rinsed out again after a contact time of a few seconds up to 45 minutes or remain completely on the hair.
  • the effect of the hair treatment agent according to the invention unfolds even during the oxidative or surfactant hair treatment and surprisingly persists even after intensive washing out of the hair treatment composition according to the invention.
  • the active substance complex according to the invention is preferably used in a cosmetic carrier.
  • the cosmetic carriers may in particular be aqueous or aqueous-alcoholic.
  • An aqueous cosmetic carrier contains at least 50% by weight of water.
  • aqueous-alcoholic cosmetic carriers include aqueous solutions containing 3 to 70% by weight of a C -C 6 -alcohol, in particular methanol, ethanol or propanol, isopropanol, butanol, isobutanol, tert-butanol, n-pentanol , Iso-pentanols, n-hexanol, isohexanols, glycol, glycerol, 1, 2-pentanediol, 1, 5-pentanediol, 1, 2-hexanediol or 1, 6-hexanediol to understand.
  • the compositions of the invention may additionally contain other organic solvents, such as methoxybutano
  • component a) of the active substance complex according to the invention dicocoyl pentaerythrityl distearyl citrate, Cutina® Shine (Cognis) is used. This is a waxy, solid at room temperature oil body.
  • the hair treatment compositions according to the invention contain dicocoyl pentaerythrityl distearyl citrates preferably in an amount of from 0.01 to 5.0% by weight, particularly preferably from 0.01 to 3.0% by weight, very particularly preferably from 0.01 to 2, 5 wt .-%, each based on the weight of the ready hair treatment agent.
  • a second essential ingredient b) in the hair treatment compositions is a quaternary ammonium compound.
  • Quaternary ammonium compounds are in principle monomeric cationic or amphoteric ammonium compounds, monomeric amines, aminoamides, polymeric cationic compounds Ammonium compounds and polymeric amphoteric ammonium compounds. From this large number of possible quaternary ammonium compounds, the following groups have proven to be particularly suitable.
  • Esterquats according to the formula (Tkat1 -2) form the first group.
  • radicals R1, R2 and R3 are each independently and may be the same or different.
  • the radicals R1, R2 and R3 mean:
  • branched or unbranched alkyl radical having 1 to 4 carbon atoms, which may contain at least one hydroxyl group, or
  • aryl or alkaryl radical for example phenyl or benzyl
  • radical (--X - R4) with the proviso that at most 2 of the radicals R1, R2 or R3 can stand for this radical:
  • the rest - (X - R4) is contained at least 1 to 3 times.
  • n 1 to 200, preferably 1 to 100, particularly preferably 1 to 50, and particularly preferably 1 to 20 with R 5 in the meaning of hydrogen, methyl or ethyl,
  • hydroxyalkyl group of one to four carbon atoms which may be branched or unbranched, and which contains at least one and at most 3 hydroxy groups.
  • Examples are: -CH 2 OH, -CH 2 CH 2 OH, -CHOHCHOH, -CH 2 CHOHCH 3 , -CH (CH 2 OH) 2 , -COH (CH 2 OH) 2 , -CH 2 CHOHCH 2 OH, CH 2 CH 2 CH 2 OH and hydroxybutyl radicals,
  • R6-0-CO- wherein R6 is a saturated or unsaturated, branched or unbranched or cyclic saturated or unsaturated alkyl radical having 6 to 30 carbon atoms, which may contain at least one hydroxy group, and which optionally further with 1 to 100 ethylene oxide units and or 1 to 100 propylene oxide units may be ethoxylated, or
  • R7-CO- wherein R7 is a saturated or unsaturated, branched or unbranched or cyclic saturated or unsaturated alkyl radical having 6 to 30 Carbon atoms which may contain at least one hydroxy group, and which may optionally be further ethoxylated with 1 to 100 ethylene oxide units and / or 1 to 100 propylene oxide units,
  • A represents a physiologically acceptable organic or inorganic anion and is defined here as representative of all structures also described below.
  • the anion of all described cationic compounds is selected from the halide ions, fluoride, chloride, bromide, iodide, sulfates of the general formula RSO 3 " , wherein R has the meaning of saturated or unsaturated alkyl radicals having 1 to 4 carbon atoms, or anionic radicals of organic acids such as Maleate, fumarate, oxalate, tartrate, citrate, lactate or acetate.
  • Such products are marketed under the trademarks Rewoquat ®, Stepantex® ®, Dehyquart® ®, ® and Armocare® Akypoquat ®.
  • the products Armocare ® VGH-70, Dehyquart ® F-75, Dehyquart ® C-4046, Dehyquart ® L80, Dehyquart ® F-30, Dehyquart ® AU-35, Rewoquat ® WE18, Rewoquat ® WE38 DPG, Stepantex ® VS 90 and Akypoquat ® 131 are examples of these esterquats.
  • R8 corresponds in its meaning R7.
  • esterquats with tradenames Armocare ® VGH-70 are, as well as Dehyquart ® F-75, Dehyquart ® L80, Stepantex ® VS 90 and Akypoquat ® 131st
  • Tkat2 Another group are quaternary imidazoline compounds.
  • the formula (Tkat2) shown below shows the structure of these compounds.
  • the radicals R independently of one another each represent a saturated or unsaturated, linear or branched hydrocarbon radical having a chain length of 8 to 30 carbon atoms.
  • the preferred compounds of the formula (Tkat2) contain for R the same hydrocarbon radical.
  • the chain length of the radicals R is preferably 12 to 21 carbon atoms.
  • A is an anion as previously described. Examples according to the invention are, for example, under the INCII names Quaternium-27, Quaternium-72, Quaternium-83 and Quaternium-91 are available. Quaternium 91 is highly preferred according to the invention.
  • compositions according to the invention furthermore comprise at least one amine and / or cationized amine, in particular an amidoamine and / or a cationized amidoamine having the following structural formulas:
  • R 1 is an acyl or alkyl radical having 6 to 30 C atoms, which may be branched or unbranched, saturated or unsaturated, and wherein the acyl radical and / or the alkyl radical may contain at least one OH group, and
  • R2, R3 and R4 are each independently
  • hydroxyalkyl group having one to 4 carbon atoms having at least one and at most three hydroxy groups, for example -CH 2 OH, -CH 2 CH 2 OH, -CHOHCHOH, -CH 2 CHOHCH 3 , -CH (CH 2 OH) 2 , -COH (CH 2 OH) 2 , -CH 2 CHOHCH 2 OH, -CH 2 CH 2 CH 2 OH and hydroxybutyl radicals, and
  • A is an anion as previously described and
  • n is an integer between 1 and 10.
  • R1 is a branched or unbranched, saturated or unsaturated acyl radical having 6 to 30 carbon atoms, which may contain at least one OH group means.
  • amidoamines and / or quaternized amidoamines in which R 2, R 3 and / or R 4 in the formula (Tkat3) represent a radical according to the general formula CH 2 CH 2 OR 5, where R 5 is the meaning of alkyl radicals having 1 to 4 carbon atoms , Hydroxyethyl or hydrogen.
  • the preferred size of n in the general formula (Tkat8) is an integer between 2 and 5.
  • the alkylamidoamines can both be present as such and converted by protonation in a correspondingly acidic solution into a quaternary compound in the composition. According to the invention, the cationic alkylamidoamines are preferred.
  • Witcamine ® 100 Incromine ® BB, Mackine ® 401 and other Mackine ® grades, Adogen ® S18V, and as a permanent cationic aminoamines: Rewoquat ® RTM 50, Empigen ® CSC, Swanol ® Lanoquat DES-50, Rewoquat ® UTM 50, Schercoquat® ® BAS ® Lexquat AMG-BEO, or Incroquat ® behenyl HE.
  • the aforementioned cationic surfactants may be used individually or in any combination with each other, wherein amounts between 0.01 to 10 wt.%, Preferably in amounts from 0.01 to 7.5% by weight, and most preferably in amounts of from 0.1 to 5.0% by weight. The very best results are obtained with amounts of from 0.1 to 3.0% by weight, based in each case on the total composition of the particular agent.
  • quaternary ammonium compounds are cationic and amphoteric polymers.
  • the cationic and / or amphoteric polymers may be homopolymers or copolymers or polymers based on natural polymers, wherein the quaternary nitrogen groups are contained either in the polymer chain or preferably as a substituent on one or more of the monomers.
  • the ammonium group-containing monomers may be copolymerized with non-cationic monomers.
  • Suitable cationic monomers are unsaturated, free-radically polymerizable compounds which carry at least one cationic group, in particular ammonium-substituted vinyl monomers such as, for example, trialkylmethacryloxyalkylammonium, trialkylacryloxyalkylammonium, dialkyldiallylammonium and quaternary
  • Vinyl ammonium monomers with cyclic, cationic nitrogen-containing groups such as pyridinium, imidazolium or quaternary pyrrolidones, e.g. Alkylvinylimidazolium, Alkylvinylpyridinium, or Alyklvinylpyrrolidon salts.
  • the alkyl groups of these monomers are preferably lower alkyl groups such as C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
  • the ammonium group-containing monomers may be copolymerized with non-cationic monomers.
  • Suitable comonomers are, for example, acrylamide, methacrylamide; Alkyl and dialkylacrylamide, alkyl and dialkylmethacrylamide, alkylacrylate, alkylmethacrylate, vinylcaprolactone, vinylcaprolactam, vinylpyrrolidone, vinylester, e.g. Vinyl acetate, vinyl alcohol, propylene glycol or ethylene glycol, wherein the alkyl groups of these monomers are preferably C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
  • R -H or -CH 3 , R 2 , R 3 and R 4 are independently selected from C 1-4-
  • Alkyl, alkenyl or hydroxyalkyl groups, m 1, 2, 3 or 4, n is a natural number and
  • Polymers are those inventively preferred for which at least one of the following
  • R is a methyl group
  • R 2 , R 3 and R 4 are methyl groups
  • m is 2.
  • Suitable physiologically tolerated counterions X " include, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ion. Preference is given to methosulfates and halide ions, in particular chloride.
  • a particularly suitable homopolymer is the, if desired cross-linked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium- 37.
  • Such products are, for example, under the names Rheocare CTH (Cosmetic Rheologies) and Synthalen® ® CR (3V Sigma) are commercially available.
  • the homopolymer is preferably used in the form of a nonaqueous polymer dispersion.
  • Such polymer dispersions are available under the names Salcare ® SC 95 and Salcare ® SC 96 in the trade.
  • Suitable cationic polymers derived from natural polymers are cationic derivatives of polysaccharides, for example, cationic derivatives of cellulose, starch or guar. Also suitable are chitosan and chitosan derivatives. Cationic polysaccharides have the general formula G-O-B-N + R a R b R c A "
  • G is an anhydroglucose residue, for example starch or cellulose anhydroglucose
  • B is a divalent linking group, for example alkylene, oxyalkylene, polyoxyalkylene or
  • R a , R b and R c are independently alkyl, aryl, alkylaryl, arylalkyl, alkoxyalkyl or alkoxyaryl each having up to 18 carbon atoms, wherein the total number of carbon atoms in R a , R b and R c is preferably not more than 20 is;
  • a " is a common counteranion and is preferably chloride.
  • Cationic, ie quaternized celluloses are available on the market with varying degrees of substitution, cationic charge density, nitrogen content and molecular weights.
  • Polyquaternium-67 is commercially available under the designations SL ® polymer or polymer ® SK (Amerchol) is.
  • Other cationic celluloses are, 400 (Amerchol, INCI name Polyquaternium-10) and polymer Quatrisoft ® LM-200 (Amerchol, INCI name Polyquaternium-24) under the names Polymer JR ®.
  • Other commercial products, the compounds Celquat ® H 100 and Celquat ® L are 200.
  • Mirustyle CP ® of the company.
  • Croda with Trimonium and Cocodimonium hydroxyethylcellulose a further derivatized cellulose with the INCI name Polyquaternium-72 before.
  • Polyquaternium-72 can be used pre-dissolved both in solid form and already in aqueous solution.
  • Particularly preferred cationic celluloses are Polyquaternium-10, Polyquaternium-24, Polyquaternium-67 and Polyquaternium-72.
  • Suitable cationic guar derivatives are marketed under the trade name Jaguar ® and have the INCI name guar hydroxypropyltrimonium chloride. Also particularly suitable cationic guar derivatives also by the company. Hercules under the name N-Hance ® commercially. Other cationic guar derivatives are marketed by the company. Cognis under the name Cosmedia® ®. A preferred cationic guar derivative is the commercial product AquaCat® ® from. Hercules. This raw material is an already pre-dissolved cationic guar derivative. The cationic guar derivatives are preferred according to the invention.
  • a suitable chitosan is sold, for example, by Kyowa Oil & Fat, Japan under the trade name Flonac ®.
  • a preferred chitosan is chitosoniumpyrrolidone is, for example, sold under the name Kytamer ® PC by Amerchol, USA.
  • Other chitosan derivatives are among the Trade names Hydage CMF, Hydagen HCMF and Chitolam NB / 101 are commercially available.
  • honey for example the commercial product Honeyquat ® 50,
  • Vinylpyrrolidone vinylimidazoliummethochloride copolymers such as those offered under the names Luviquat.RTM ® FC 370, FC 550 and the INCI name Polyquaternium-16 and FC 905 and HM 552,
  • vinylpyrrolidone / dimethylaminoethyl for example vinylpyrrolidone / dimethylaminoethyl copolymer available under the trade names Gafquat ® 755 N and Gafquat ® 734, United States is marketed by Gaf Co. and the INCI - name Polyquaternium-1 1,
  • Vinylpyrrolidone-vinylcaprolactam-acrylate terpolymers such as those offered with acrylic acid esters and acrylamides as the third monomer building commercially, for example, under the name Aquaflex ® SF 40.
  • Amphoteric polymers according to the invention are those polymers in which a cationic group is derived from at least one of the following monomers:
  • R -CH CR 2 -CO-Z- (C n H 2n ) -N (+) R 2 R 3 R 4 A ( (-) (monol)
  • R and R 2 independently of one another represent hydrogen or a methyl group and R 3 , R 4 and R 5 independently of one another represent alkyl groups having 1 to 4 carbon atoms, Z denotes an NH group or an oxygen atom, n denotes an integer of 2 to 5 and A (_) is the anion of an organic or inorganic acid,
  • R 8 -CH CR 9 -COOH (mono 3)
  • R 8 and R 9 are independently hydrogen or methyl groups.
  • amphoteric polymers are copolymers of at least one monomer (monol) or (mono 2) with the monomer (mono 3), in particular copolymers of the monomers (mono 2) and (mono 3).
  • amphoteric polymers are copolymers of diallyl dimethyl ammonium chloride and acrylic acid. These copolymers are sold under the INCI name Polyquaternium-22, inter alia with the trade name Merquat® 280 (Nalco).
  • amphoteric polymers according to the invention may additionally contain one monomer (mono 4).
  • R 0 and R independently of one another are hydrogen or methyl groups and R 2 is a hydrogen atom or a (C 8 -C 8 ) -alkyl group.
  • Amphoteric polymers based on a comonomer (Mono4) which are very particularly preferably used according to the invention are terpolymers of diallyldimethylammonium chloride, acrylamide and acrylic acid. These copolymers are sold under the INCI name Polyquaternium-39, inter alia, under the trade name Merquat® Plus 3330 (Nalco).
  • amphoteric polymers can generally be used both directly and in salt form, which is obtained by neutralization of the polymers, for example with an alkali metal hydroxide, according to the invention.
  • a highly preferred amphoteric polymer according to the invention is a copolymer which is composed as follows: 0.1 to 50% (based on the total number of monomers in the copolymer) of monomers of the formula (I)
  • R is preferably a methyl group, and also R 2 , R 3 , R 4 , R 5 and R 6 are methyl groups.
  • the group Z is preferably an -NH group, the index n is particularly preferably the number 3.
  • a preferred monomer which satisfies the criteria mentioned in the preceding paragraph also has, as group B, a -CH 2 -CH (OH) -CH 2 group, and the subscript m is the number 0.
  • Polymers preferred according to the invention are composed of monomers A1)
  • A1 from 0.1 to 50%, preferably from 10 to 50% (based on the total number of monomers in the copolymer) of monomers of the formula (Ia)
  • X is chloride, sulphate, methosulphate,
  • the monomers A2) from the group of acrylic acid, methacrylic acid and the alkali metal and ammonium salts of these acids,
  • the monomer A2 is 50 to 99.9%, preferably 50 to 90% (based on the total number of monomers in the copolymer) of the copolymer.
  • a further preferred monomer which corresponds to the criteria mentioned in the aforementioned paragraph, furthermore possesses, as group B, a -CH 2 -CH (OH) -CH 2 group, as group A a - (CH 2 ) 2- or a - ( CH 2 ) 3 - or a - (CH 2 ) 4 group, and the index m is the number 1.
  • at least one copolymer A is selected from:
  • A1 from 0.1 to 50%, preferably from 10 to 50% (based on the total number of monomers in the copolymer) of monomers of the formula (Ib)
  • p 2, 3 or 4
  • X is chloride, sulphate, methosulphate,
  • the monomer A2 represents 50 to 99.9%, preferably 50 to 90% (based on the total number of monomers in the copolymer) of the copolymer;
  • Particularly preferred monomers A2 are acrylic acid or its salts (also mixed, i.e. partially neutralized acrylic acids) and acrylamide.
  • a preferred copolymer A is a copolymer of the monomer (Ia), sodium acrylate and acrylamide, the following distribution (in% of the total monomers contained in the polymer) being preferred:
  • Acrylamide 0 to 50%, preferably 0 to 30%
  • a preferred copolymer A contains the following number of the respective monomers:
  • Monomer (Ia) Values from 1 to 12500, preferably from 2 to 8000, more preferably from 3 to 4000 and in particular from 5 to 2000
  • Sodium acrylate Values from 1 to 24,000, preferably from 5 to 15,000, more preferably from
  • amphopolymers according to the invention are particularly preferred if they contain at least one copolymer A of the general formula (Ic)
  • Q is from 3 to 55,000, preferably from 10 to 25,000, particularly preferably from 50 to 15,000, more preferably from 100 to 10,000, even more preferably from 500 to 8000 and in particular from 1000 to 5000,
  • x stands for (0 to 0.5) Q, preferably for (0 to 0.3) Q and in particular for the values 0, 1, 2, 3, 4, 5, wherein the value 0 is preferred,
  • y stands for (0.1 to 0.95) Q, preferably for (0.5 to 0.7) Q and in particular for values of 1 to 24000, preferably of 5 to 15000, particularly preferably of 10 to 10000 and in particular of 100 to 4800,
  • compositions according to the invention may also comprise a copolymer which consists of monomers of the formula (Ia) Maleic or fumaric acid (or their disodium salts) and acrylamide is constructed. In this case, the following distribution (in% of the total monomers contained in the polymer) is preferred:
  • Acrylamide 0 to 50%, preferably 0 to 30
  • a preferred copolymer A contains the following number of the respective monomers:
  • Monomer (Ia) Values from 1 to 12500, preferably from 2 to 8000, more preferably from 3 to 4000 and in particular from 5 to 2000
  • Maleic acid or fumaric acid (or their disodium salt): values of from 1 to 24,000, preferably from 5 to 15,000, more preferably from 10 to 10,000 and in particular from 100 to 4800
  • a most preferred polymer which is constructed as described previously, under the INCI - free commercially, for example from Rhodia available as Polycare ® Boost designation Polyquaternium-74.
  • the abovementioned cationic and / or amphoteric polymers can be used individually or in any desired combinations with one another, amounts of between 0.01 to 10% by weight, preferably, amounts of 0.01 to 7.5% by weight, and very particularly preferably in Quantities of 0.1 to 5.0 wt.% Are included. The very best results are obtained with amounts of from 0.1 to 3.0% by weight, based in each case on the total composition of the particular agent.
  • the ingredient c) of the combination of active substances according to the invention is another of the dicocoyl pentaerythrityl distearyl citrates of various oil bodies already described as mandatory. These are, for example, with particular preference ester oils.
  • the ester oils are defined as follows: Ester oils are to be understood as meaning the esters of C 6 - C 30 fatty acids with C 2 - C 30 fatty alcohols. The monoesters of the fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • fatty acid components used in the esters are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic, Elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • fatty alcohol components in the ester oils are isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, Gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures.
  • isopropyl myristate IPM ® Rilanit
  • isononanoic acid C16-18 alkyl ester Cetiol ® SN
  • 2-ethylhexyl palmitate Cegesoft ® 24
  • stearic acid 2-ethylhexyl ester Cetiol ® 868
  • cetyl oleate glycerol tricaprylate, Kokosfettalkohol- caprate / caprylate (Cetiol ® LC), n-butyl stearate, oleyl erucate (Cetiol ® J 600)
  • isopropyl palmitate IPP Rilanit ®
  • oleyl Oleate Cetiol ®
  • hexyl laurate Cetiol ® A
  • di-n-butyl adipate Cetiol ® B
  • myristyl palmitate IPP Ri
  • ester oils may also be alkoxylated with ethylene oxide, propylene oxide, or mixtures of ethylene oxide and propylene oxide.
  • the alkoxylation can be found both on the fatty alcohol part and on the fatty acid part and on both parts of the ester oils.
  • R 1 is a saturated or unsaturated, branched or unbranched, cyclic saturated cyclic unsaturated acyl radical having 6 to 30 carbon atoms,
  • AO is ethylene oxide, propylene oxide or butylene oxide
  • X is a number between 1 and 200, preferably 1 and 100, more preferably between 1 and 50, most preferably between 1 and 20, most preferably between 1 and 10 and most preferably between 1 and 5,
  • R 2 represents a saturated or unsaturated, branched or unbranched cyclic saturated cyclic unsaturated alkyl, alkenyl, alkynyl, phenyl or benzyl radical having from 6 to 30 carbon atoms.
  • fatty acid moieties used as radical R1 in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid , Gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • fatty alcohol moieties R2 in the ester oils are benzyl alcohol, isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol , Arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical see mixtures.
  • a particularly preferred ester oil according to the invention is obtainable, for example, under the INCI name PPG-3 benzyl ether myristate.
  • ester oils are to be understood as meaning:
  • Dicarboxylic acid esters such as di-n-butyl adipate, di- (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecyl acelate
  • diol esters such as ethylene glycol dioleate, ethylene glycol diisotridecanoate, propylene glycol di (2- ethylhexanoate), propylene glycol diisostearate,
  • Fatty acid partial glycerides ie monoglycerides, diglycerides and their technical mixtures. Typical examples are mono- and / or diglycerides based on caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, Gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • oleic acid monoglycerides are used.
  • Ester oils are particularly preferably used according to the invention. Particularly preferred from this group are isopropyl myristate and isopropyl palmitate, esters of caproic and caprylic with fatty acids and caproic and polycloric acid with fatty alcohols, especially coco-caprylates, cetyl oleate, oleylerucate and the esters of carbonic acid such as glycerol carbonate and dicaprylyl carbonate.
  • the ester oils are present in the compositions according to the invention in an amount of from 0.01 to 20% by weight, preferably from 0.01 to 10.0% by weight, particularly preferably from 0.01 to 7.5% by weight, most preferably from 0, 1 to 5.0 wt.% Used.
  • oils examples include sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil. Also suitable, however, are other triglyceride oils such as the liquid portions of beef tallow as well as synthetic triglyceride oils.
  • the compounds are available as commercial products 1, 3-di- (2-ethyl-hexyl) - cyclohexane (Cetiol ® S), and di-n-octyl ether (Cetiol ® OE) may be preferred.
  • natural oils for example, amaranth seed oil, apricot kernel oil, argan oil, avocado oil, babassu oil, cottonseed oil, borage seed oil, camelina oil, thistle oil, peanut oil, pomegranate seed oil, grapefruit seed oil, hemp oil, hazelnut oil, elderflower seed oil, currant seed oil, jojoba oil, cocoa butter, linseed oil, macadamia nut oil, corn oil, almond oil, Marula oil, evening primrose oil, olive oil, palm oil, rapeseed oil, rice oil, sea buckthorn pulp oil, sea buckthorn seed oil, sesame oil, shea butter, soybean oil, sunflower oil, grapeseed oil, walnut oil or wild rose oil used.
  • natural oils for example, amaranth seed oil, apricot kernel oil, argan oil, avocado oil, babassu oil, cottonseed oil, borage seed oil, camelina oil, thistle oil, peanut oil, pomegranate seed oil, grapefruit seed
  • fruit acids are also known to the person skilled in the art as edible acids. These are often hydroxycarboxylic acids. In particular, these acids include lactic acid, malic acid, maleic acid, citric acid, butyric acid, oxalic acid, salicylic acid, glycolic acid, glyceric acid, tartaric acid, azelaic acid and others. In addition to the acids, it is also possible to use the physiologically tolerated salts of these acids. These include the sodium, potassium, calcium, magnesium, lithium and / or ammonium salts.
  • the fruit acids are used in the compositions according to the invention in an amount of 0.05 to 10% by weight, preferably 0.05 to 5% by weight and more preferably 0.1 to 3.0% by weight, based in each case on the total composition.
  • the wrkung can be significantly increased.
  • This group is known to the skilled person as a preservative. Not all preservatives, however, show these good properties.
  • the so-called mild preservatives which often have preservative-supporting properties, have proven to be effective in the present invention. These are in particular phenoxyethanol, benzyl alcohol, sorbitol, phenethyl alcohol, phenoxyisopropanol, sorbic acid and their physiologically tolerated salts, benzoic acid and their physiologically tolerated salts.
  • the hair treatment compositions according to the invention also contain, in addition to the combination of active substances according to the invention, further components customary in cosmetic compositions.
  • the selection of these ingredients generally depends on the intended use of the hair treatment agents.
  • further surface-active substances will be contained.
  • further cationic compounds and other care substances may be present.
  • the agents contain at least one surface-active substance, with both anionic and zwitterionic, ampholytic, nonionic and cationic surface-active substances being suitable in principle.
  • the choice of surfactants depends on the nature of the agent. Suitable anionic surfactants (tanion) in preparations according to the invention are all anionic surfactants suitable for use on the human body. Typical examples of anionic surfactants are:
  • Sulfobernsteinklamono- and dialkyl esters having 8 to 24 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethylester having 8 to 24 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups.
  • Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms are alpha-sulfofatty acids having 8 to 30 carbon atoms.
  • Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R-O (CH 2 -CH 2 O) x -OSO 3 H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x 0 or 1 to 12,
  • esters of tartaric acid and citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide with fatty alcohols having 8 to 22 C atoms,
  • R 2 is hydrogen, a radical (CH 2 CH 2 0) nR 2 or X, n is from 1 to 10 and X is hydrogen, an alkali or alkaline earth metal or NR 3 R 4 R 5 R 6 , where R 3 to R 6 independently of one another represent hydrogen or a C 4 - hydrocarbon radical,
  • RCO-- for a linear or branched, aliphatic, saturated and / or unsaturated acyl radical having 6 to 22 C atoms
  • Alk for CH 2 CH 2 , CHCH 3 CH 2 and / or CH 2 CHCH 3
  • n for numbers of 0 , 5 to 5 and M is a metal such as alkali metal, in particular sodium, potassium, lithium, alkaline earth metal, in particular magnesium, calcium, zinc, or ammonium ion, such as + NR 3 R 4 R 5 R 6 , with R 3 to R 6 independently of one another represent hydrogen or a C1 to C4 hydrocarbon radical
  • R 8 CO is a linear or branched acyl radical having 6 to 22 carbon atoms
  • x, y and z are in total 0 or numbers of 1 to 30, preferably 2 to 10
  • X is an alkali or alkaline earth metal.
  • monoglyceride (ether) sulfates suitable for the purposes of the invention are the reaction products of lauric acid monoglyceride, coconut fatty acid monoglyceride, palmitic acid monoglyceride, stearic acid monoglyceride, oleic acid monoglyceride and tallow fatty acid monoglyceride and their ethylene oxide adducts with sulfur trioxide or chlorosulfonic acid in the form of their sodium salts.
  • monoglyceride sulfates are used, in which R 8 CO is a linear acyl radical having 8 to 18 carbon atoms,
  • Such products are obtainable, for example, by the company Chem Y under the product name Akypo ®.
  • Condensation products of a water-soluble salt of a water-soluble protein hydrolyzate with a C8-C30 fatty acid are available under the trademark Lamepon® ®, Maypon ®, Gluadin® ®, Hostapon® ® KCG or Amisoft ® long been commercially.
  • the mild anionic surfactants contain polyglycol ether chains, it is particularly preferred that they have a narrow homolog distribution. Further, in the case of mild anionic surfactants having polyglycol ether units, it is preferable that the number of glycol ether groups is 1 to 20, preferably 2 to 15, more preferably 2 to 12. Particularly mild anionic surfactants having polyglycol ether groups with no restricted homolog distribution can be obtained, for example on the one hand the number of polyglycol ether groups is 4 to 12 and Zn or Mg ions are selected as the counterion. One example is the commercial product Texapon.RTM ® ASV.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyl dimethylammonium glycinate, N-acylaminopropyl N, N-dimethylammonium glycinates, for example cocoacylaminopropyl dimethylammonium glycinate, and 2-alkyl 3-carboxymethyl-3-hydroxyethyl-imidazolines having in each case 8 to 18 C atoms in the alkyl or acyl group, and also the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
  • Ampholytic surfactants are understood as meaning those surface-active compounds which are capable of forming internal salts.
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkylimino-dipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group.
  • amphoteric or zwitterionic surfactants are alkylbetaines, alkylamidobetaines, aminopropionates, aminoglycinates, imidazolinium betaines and sulfobetaines.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 2 -C 18 -acylsarcosine.
  • Nonionic surfactants are for example
  • R is CO for a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22 carbon atoms
  • R 2 is hydrogen or methyl
  • R 3 is linear or branched alkyl radicals having 1 to 4 carbon atoms
  • w is a number from 1 to 20 .
  • R 0 [CH 2 CH (CH 3 ) O] x (CH 2 CHR 2 O) y [CH 2 CH (OH) R 3 ] z with R standing for a linear or branched, saturated or unsaturated alkyl and / or or alkenyl radical having 2 to 30 C atoms
  • R 2 is hydrogen, a methyl, ethyl, propyl or iso-propyl radical
  • R 3 is a linear or branched alkyl radical having 2 to 30 C atoms
  • x is 0 or a number from 1 to 20
  • Y stands for a number from 1 to 30
  • z stands for the number 1, 2, 3, 4 or 5.
  • Fatty acid amide polyglycol ethers Fatty acid amide polyglycol ethers, fatty amine polyglycol ethers, Mixed ethers or mixed formals and polysorbates.
  • Cationic surfactants of the formula (Tkat1 -1) can additionally be used.
  • R 1, R 2, R 3 and R 4 each independently represent hydrogen, a methyl group, a phenyl group, a benzyl group, a saturated, branched or unbranched alkyl group having a chain length of 8 to 30 carbon atoms optionally with one or more hydroxy groups may be substituted.
  • A is a physiologically acceptable anion, for example halides such as chloride or bromide and methosulfates.
  • Examples of compounds of the formula (Tkat1) are lauryltrimethylammonium chloride, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetyltrimethylammonium methosulfate, dicetyldimethylammonium chloride, tricetylmethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, behenyltrimethylammonium bromide, behenyltrimethylammonium methosulfate.
  • the surfactants (T) are used in amounts of 0.05-45% by weight, preferably 0.1-30% by weight and very particularly preferably 0.5-25% by weight, based on the total agent used according to the invention ,
  • Emulsifiers which can be used according to the invention are, for example
  • Glucosides mixtures of alkyl (oligo) and fatty alcohols for example, the commercially available product ® Montanov 68,
  • Phospholipids lecithins, phopshatidylcholines
  • Fatty acid esters of sugars and sugar alcohols such as sorbitol
  • Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention contain fatty substances (fat) as further active ingredient.
  • Fat substances (fat) are understood to mean fatty acids, fatty alcohols, natural and synthetic waxes, which can be in solid form as well as liquid in aqueous dispersion, and natural and synthetic cosmetic oil components.
  • fatty acids can be used linear and / or branched, saturated and / or unsaturated fatty acids having 6 to 30 carbon atoms. Preference is given to fatty acids having 10 to 22 carbon atoms. Among these could be mentioned, for example, isostearic as the commercial products Emersol ® 871 and Emersol ® 875, and isopalmitic acids such as the commercial product Edenor ® IP 95, and all other products sold under the trade names Edenor ® (Cognis) fatty acids.
  • fatty acids are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic as well as their technical mixtures.
  • Particularly preferred are usually the fatty acid cuttings obtainable from coconut oil or palm oil; In particular, the use of stearic acid is usually preferred.
  • the amount used is 0.1 - 15 wt.%, Based on the total mean.
  • the amount is preferably 0.5-10% by weight, with amounts of 1-5% by weight being particularly advantageous.
  • fatty alcohols fatal
  • saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with C 6 -C 30 -, preferably C 0 -C 22 -and very particularly preferably C 2 -C 22 -carbon atoms.
  • Decanols, octanols, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, caprylic alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol are, for example, decanol, octanolol, dodecadienol, decadienol , as well as their Guerbet alcohols, this list should have exemplary and non-limiting character.
  • the fatty alcohols are derived from preferably natural fatty acids, usually from recovery from the esters the fatty acids can be assumed by reduction.
  • those fatty alcohol cuts which represent a mixture of different fatty alcohols.
  • Such substances are, for example, under the names Stenol ® such as Stenol ® 1618 or Lanette ® such as Lanette ® O or Lorol ®, for example, Lorol ® C8, Lorol C14 ®, Lorol C18 ®, ® Lorol C8-18, HD-Ocenol ®, Crodacol ® such as Crodacol ® CS, Novol ®, Eutanol ® G, Guerbitol ® 16, Guerbitol ® 18, Guerbitol ® 20, Isofol ® 12, Isofol ® 16, Isofol ® 24, Isofol ® 36, Isocarb ® 12, Isocarb ® 16 or acquire Isocar
  • wool wax alcohols as are commercially available, for example under the names of Corona ®, White Swan ®, Coronet ® or Fluilan ® can be used according to the invention.
  • the fatty alcohols are used in amounts of from 0.1 to 30% by weight, based on the total preparation, preferably in amounts of from 0.1 to 20% by weight.
  • waxes As natural or synthetic waxes (Fatwax), solid paraffins or isoparaffins, carnauba waxes, beeswaxes, candelilla waxes, ozokerites, ceresin, spermaceti, sunflower wax, fruit waxes such as apple wax or citrus wax, microwaxes of PE or PP can be used according to the invention.
  • Such waxes are available, for example, from Kahl & Co., Trittau.
  • the amount used is 0.1-50 wt.% Based on the total agent, preferably 0.1 to 20 wt.% And particularly preferably 0.1 to 15 wt.% Based on the total agent.
  • the total amount of oil and fat components in the compositions according to the invention is usually 0.5-75% by weight, based on the total agent. Amounts of 0.5-35 wt .-% are preferred according to the invention.
  • compositions according to the invention with the active ingredient complex according to the invention are protein hydrolysates and / or derivatives thereof (P).
  • protein hydrolysates of both vegetable and animal or marine or synthetic origin can be used.
  • Animal protein hydrolysates are, for example, elastin, collagen, keratin, silk and milk protein powders, which may also be in the form of salts.
  • Such products are, for example, under the trademarks Dehylan ® (Cognis), Promois® ® (Interorgana) Collapuron ® (Cognis), Nutrilan® ® (Cognis), Gelita-Sol ® (German Gelatinefabriken Stoess & Co), Lexein ® (Inolex) and kerasol tm ® (Croda) sold.
  • Further preferred vegetable protein hydrolysates according to the invention are, for example, soybean, almond, pea, moringa, potato and wheat protein hydrolysates.
  • Such products are, for example, under the trademarks Gluadin ® (Cognis), diamine ® (Diamalt) ® (Inolex), Hydrosoy ® (Croda), hydro Lupine ® (Croda), hydro Sesame ® (Croda), Hydro tritium ® (Croda), Crotein ® (Croda) and Puricare ® LS 9658 from Laboratoires Serobi unanimouss.
  • protein hydrolysates according to the invention are of maritime origin. These include, for example, collagen hydrolyzates of fish or algae as well as protein hydrolysates of Mussels or pearl hydrolyzates. Examples of novel beads Extra cts are the commercial products Pearl Protein Extract BG ® or Crodarom ® Pearl.
  • cationized protein hydrolysates are to be counted among the protein hydrolysates and their derivatives, wherein the underlying protein hydrolyzate from the animal, for example from collagen, milk or keratin, from the plant, for example from wheat, maize, rice, potatoes, soya or almonds, from marine life forms , for example from fish collagen or algae, or biotechnologically derived protein hydrolysates, may originate.
  • the cationic protein hydrolysates and derivatives according to the invention those mentioned under the INCI names in the "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toiletry and Fragrance Association 1 101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and commercially available products.
  • the protein hydrolysates (P) are present in the compositions in concentrations of 0.001% by weight to 20% by weight, preferably from 0.05% by weight to 15% by weight and most preferably in amounts of 0.05% by weight. up to 5% by weight.
  • vitamins are vitamins, provitamins or vitamin precursors.
  • Vitamins, pro-vitamins and vitamin precursors are particularly preferred, which are assigned to the groups A, B, C, E, F and H.
  • the group of substances designated as vitamin A includes retinol (vitamin A and 3,4-didehydroretinol (vitamin A 2 ) .beta.-carotene is the provitamin of retinol.)
  • the vitamin A component is, for example, vitamin A acid and their esters, vitamin A-aldehyde and vitamin A-alcohol as well as its esters such as the palmitate and the acetate
  • the agents according to the invention contain the vitamin A component preferably in amounts of 0.05-1% by weight, based on the entire preparation.
  • the vitamin B group or the vitamin B complex include u. a .:
  • Vitamin B 2 (riboflavin)
  • Vitamin B 3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone.
  • Panthenol and / or pantolactone are preferably used in the context of this group.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate, as well as cationic panthenol derivatives.
  • Pantothenic acid is preferably used as a derivative in the form of the more stable calcium salts and sodium salts (Ca-pantothenate, Na-pantothenate) in the present invention.
  • Vitamin B 6 (pyridoxine and pyridoxamine and pyridoxal).
  • the said compounds of the vitamin B type, in particular vitamin B 3 , B 5 and B 6 are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] - imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • compositions according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and H. Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred.
  • a particularly preferred group of ingredients in the cosmetic compositions according to the invention are the betaines mentioned below: carnitine, carnitine tartrate, carnitine magnesium citrate, acetyl carnitine, betalain, 1,1-dimethyl-proline, choline, choline chloride, choline bitartrate, choline dihydrogen citrate and those described in the literature Betain designated compound N, N, N-tri methy Ig lyci n.
  • Carnitine, histidine, choline and betaine are preferably used.
  • the active ingredient used is L-carnitine tartrate.
  • compositions according to the invention contain biochinones.
  • suitable biochinones are understood as meaning one or more ubiquinone (s) and / or plastoquinone (s).
  • the preferred ubiquinones according to the invention have the following formula:
  • Coenzyme Q-10 is most preferred.
  • compositions of the invention contain purine and / or purine derivatives in narrower ranges.
  • preferred cosmetic agents are characterized characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0, 1 wt .-% purine (s) and / or purine derivative (s) included.
  • Cosmetic agents preferred according to the invention are characterized in that they contain purine, adenine, guanine, uric acid, hypoxanthine, 6-purinethiol, 6-thioguanine, xanthine, caffeine, theobromine or theophylline. In hair cosmetic preparations, caffeine is most preferred.
  • the cosmetic agent contains ectoine ((S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid.
  • agents which, based on their weight, are from 0.00001 to 10.0% by weight, preferably from 0.0001 to 5.0% by weight and in particular from 0.001 to 3% by weight, of the active compounds from Group formed by carnitine, coenzyme Q-10, ectoine, a vitamin B series, a purine and its derivatives or physiologically acceptable salts.
  • a particularly preferred care additive in the hair treatment compositions according to the invention is taurine.
  • Taurine is understood to mean exclusively 2-aminoethanesulfonic acid and a derivative to the explicitly mentioned derivatives of taurine.
  • Derivatives of taurine include N-monomethyltaurine, ⁇ , ⁇ -dimethyltaurine, tauryllysylate, taurine tartrate, taurine ornithine, lysyl taurine and ornithyl taurine.
  • agents according to the invention which - based on their weight - 0.0001 to 10.0 wt .-%, preferably 0.0005 to 5.0 wt .-%, particularly preferably 0.001 to 2.0 wt .-% and In particular, 0.001 to 1, 0 wt .-% taurine and / or a derivative of taurine included.
  • the effect of the compositions according to the invention can be further increased by a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • the sodium salt is most preferred.
  • the amounts used in the inventive compositions are 0.05 to 10 wt.%, Based on the total agent, particularly preferably 0.1 to 5, and in particular 0.1 to 3 wt.%.
  • the hair treatment compositions according to the invention can be formulated in a particularly natural and yet very effective way in their care performance.
  • customary preservatives can be dispensed with.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • anionic polymers examples include acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methylpropansulfon acid which is commercially available, for example under the name Rheothik ® 1 1 -80 is.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ® commercially.
  • Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers.
  • a 1, 9-decadiene crosslinked maleic acid methyl vinyl ether copolymer is available under the name ® Stabileze QM.
  • the anionic polymers are preferably contained in the agents according to the invention in amounts of from 0.05 to 10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred. In a further embodiment, the agents according to the invention may contain nonionogenic polymers.
  • Suitable nonionic polymers are, for example:
  • Vinylpyrrolidone / vinyl ester copolymers as sold, for example, under the trademark Luviskol ® (BASF).
  • Luviskol ® VA 64 and Luviskol ® VA 73, each vinylpyrrolidone / vinyl acetate copolymers are also preferred nonionic polymers.
  • Cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylcellulose Methylhy-, as sold for example under the trademark Culminal® ® and Benecel ® (AQUALON) and Natrosol ® grades (Hercules).
  • Starch and its derivatives in particular starch, such as Structure XL ® (National Starch), a multifunctional, salt-tolerant starch;
  • the nonionic polymers are preferably contained in the compositions according to the invention in amounts of from 0.05 to 10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred.
  • the agents according to the invention should additionally contain at least one UV light protection filter.
  • UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances are e.g. to call:
  • 3-benzylidene camphor e.g. B. 3- (4-methylbenzylidene) camphor;
  • 4-aminobenzoic acid derivatives preferably 2-ethylhexyl 4- (dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and 4- (dimethylamino) benzoic acid ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid 2-ethylhexyl ester, 4-methoxycinnamic acid propyl ester, 4-methoxycinnamic acid isoamyl ester, 2-cyano-3-phenyl-cinnamic acid 2-ethylhexyl ester (octocrylene);
  • Esters of salicylic acid preferably 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomenthyl salicylate;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably di-2-ethylhexyl 4-methoxybenzmalonate
  • Triazine derivatives e.g. 2,4,6-Trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1, 3,5-triazine and
  • Propane-1,3-diones e.g. 1- (4-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione;
  • Suitable water-soluble substances are:
  • Sulfonic acid derivatives of the 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bomylidene) -sulfonic acid and its salts.
  • UV-A filter in particular derivatives of benzoylmethane come into question, such as 1 - (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione or 1-phenyl-3 (4'-isopropylphenyl) -propane-1,3-dione.
  • the UV-A and UV-B filters can also be used in mixtures.
  • insoluble pigments are also suitable for this purpose, in particular finely dispersed metal oxides or salts, for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), barium sulfate and zinc stearate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They may have a spherical shape, but it is also possible to use those particles which have an ellipsoidal or otherwise deviating shape from the spherical shape.
  • the cosmetic agents may contain other active ingredients, auxiliaries and additives, such as
  • Structurants such as maleic acid and lactic acid
  • Swelling agents such as urea, allantoin, carbonates or hydantoin
  • Anti-dandruff agents such as Piroctone Olamine, Zinc Omadine and Climbazole,
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • Pearlescing agents such as ethylene glycol mono- and distearate and PEG-3-distearate,
  • Propellants such as propane-butane mixtures, N 2 O, dimethyl ether, C0 2 and air,
  • the pH of the compositions according to the invention is 1.5 to 8.5, preferably 2.0 to 7.5 and particularly preferably 2.0 to 6.5.
  • a second subject of the invention is therefore a method for hair treatment, in which a hair treatment composition according to claim 1 is applied to the hair and is rinsed by the hair after a contact time.
  • the exposure time is preferably a few seconds to 100 minutes, more preferably 1 to 50 minutes and most preferably 1 to 30 minutes.
  • a cosmetic composition according to claim 1 is applied to the hair and remains there.
  • “remaining on the hair” means that the agent is not rinsed out of the hair immediately after it has been used, but in this case the agent remains on the hair for more than 100 minutes until the next hair wash.
  • the pH of all the above formulations is between 4.3 and 2.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrityl-distéaryle. Le citrate de dicocoyl-pentaérythrityl-distéaryle est utilisé dans les produits de traitement capillaire de l'invention en tant qu'élément d'un complexe de principes actifs. Les compositions selon l'invention se caractérisent également en ce qu'elles ne contiennent pas de silicone.
EP11787643.3A 2010-12-14 2011-11-11 Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle Ceased EP2651385A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201010063059 DE102010063059A1 (de) 2010-12-14 2010-12-14 Haarbehandlungsmittel enthaltend Dicocoyl Pentaerythrityl Distearyl Citrate
PCT/EP2011/069933 WO2012079872A2 (fr) 2010-12-14 2011-11-11 Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle

Publications (1)

Publication Number Publication Date
EP2651385A2 true EP2651385A2 (fr) 2013-10-23

Family

ID=45023812

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11787643.3A Ceased EP2651385A2 (fr) 2010-12-14 2011-11-11 Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle

Country Status (3)

Country Link
EP (1) EP2651385A2 (fr)
DE (1) DE102010063059A1 (fr)
WO (1) WO2012079872A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6055662B2 (ja) * 2012-11-20 2016-12-27 株式会社ミルボン 毛髪用処理剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19623383C2 (de) * 1996-06-12 1999-07-01 Henkel Kgaa Verwendung von Fettstoffen als Siliconersatz zur Herstellung von kosmetischen und/oder pharmazeutischen Zubereitungen
DE10105922A1 (de) * 2001-02-09 2002-08-22 Henkel Kgaa Haarkosmetische Siliconersatzstoffe
DE10150726A1 (de) * 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Konditionierendes Haarwaschmittel
EP1374846A1 (fr) * 2002-06-19 2004-01-02 Cognis Iberia, S.L. Compositions huileuses avec und viscosité élevée
JP5629427B2 (ja) * 2008-10-31 2014-11-19 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングCognis IP Management GmbH 毛髪処理組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012079872A2 *

Also Published As

Publication number Publication date
DE102010063059A1 (de) 2012-06-14
WO2012079872A3 (fr) 2013-06-13
WO2012079872A2 (fr) 2012-06-21

Similar Documents

Publication Publication Date Title
DE102012203240A1 (de) Haarpflegemittel mit Antischuppenmitteln und ausgewählten Aminosilikonen
WO2011113501A1 (fr) Produits de soins capillaires contenant au moins quatre huiles sélectionnées
WO2013143776A2 (fr) Agents de traitement capillaire contenant des amides d'acides gras sélectionnés et des composés d'ammoniums quaternaires sélectionnés
EP2830581A1 (fr) Produits de traitement capillaire contenant des amides d'acide gras et des filtres uv sélectionnés
DE102012203986A1 (de) Haarbehandlungsmittel enthaltend Cyperus esculentus tuber oil
EP2480288A2 (fr) Agents de traitement de fibres kératiniques contenant du hyaluronate de diméthylsilanol et de la glycérine
WO2013143764A1 (fr) Produits de traitement capillaire contenant des amides d'acide gras et des corps gras sélectionnés
WO2013143735A1 (fr) Produits de traitement capillaire contenant des amides d'acide gras et des composés d'ammonium quaternaire
WO2013143738A1 (fr) Produits de traitement capillaire contenant des amides d'acide gras et des acides hydroxycarboxyliques sélectionnés
WO2013143780A1 (fr) Produits de traitement capillaire contenant des amides d'acide gras et des silicones sélectionnés
DE102012203989A1 (de) Haarbehandlungsmitel enthaltend Cyperus esculentus tuber extract
WO2014023488A2 (fr) Agents de soins capillaires contenant des silicones choisis et des complexes choisis composés d'hydrolysats protéiques acides et d'amidoamines d'acides gras basiques
WO2011054645A2 (fr) Produit de traitement capillaire contenant du polyquaternium-72
WO2012079872A2 (fr) Produits de traitement capillaire contenant du citrate de dicocoyl-pentaérythrithyl-distéaryle
EP2882409A2 (fr) Agents de soins capillaires contenant des agents anti-pelliculaires et des complexes choisis composés d'hydrolysats protéiques acides et d'amidoamines d'acides gras basiques
DE102009027942A1 (de) Haarbehandlungsmittel enthaltend einen Extrakt aus Cimicifuga
DE102011085215A1 (de) Haarbehandlungsmittel enthaltend Kamutprotein
WO2014023491A2 (fr) Agents de soins capillaires contenant des composés ammonium quaternaires choisis et des complexes choisis composés d'hydrolysats protéiques acides et d'amidoamines d'acides gras basiques
EP2882407A2 (fr) Agents de soins capillaires contenant des filtres à uv choisis et des complexes choisis composés d'hydrolysats protéiques acides et d'amidoamines d'acides gras basiques
DE102009027970A1 (de) Kosmetische Zusammensetzung enthaltend ethoxyliertes Amaranthöl
DE102009027943A1 (de) Haarbehandlungsmittel mit Kokum Butter
WO2013127613A2 (fr) Produits capillaires contenant des alkyloligoglucosides cationiques sélectionnés et des silicones cationiques sélectionnées
DE102011085216A1 (de) Haarbehandlungsmittel enthaltend ausgewählte Gemüseextrakte
DE102011085218A1 (de) Haarbehandlungsmittel enthaltend Dinkelprotein
DE102011081466A1 (de) Haarbehandlungsmittel mit einem Öl aus Maqui Beeren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130515

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 8/41 20060101ALI20140317BHEP

Ipc: A61K 8/49 20060101ALI20140317BHEP

Ipc: A61K 8/37 20060101AFI20140317BHEP

Ipc: A61Q 5/00 20060101ALI20140317BHEP

Ipc: A61Q 5/12 20060101ALI20140317BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150129